# Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)

> **NCT02060370** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 60 (actual)

## Conditions studied

- Genitourinary Cancer
- Kidney Cancer

## Interventions

- **DRUG:** Sunitinib
- **BEHAVIORAL:** Questionnaire

## Key facts

- **NCT ID:** NCT02060370
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2019-01-02
- **Final completion:** 2019-01-02
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2020-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02060370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02060370, "Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02060370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*